We Think Prometheus Biosciences Can Afford To Drive Business Growth

Slightly above 67% of Prometheus Biosciences' investor base is looking to short. The analysis of current outlook of investing in Prometheus Biosciences suggests that many traders are alarmed regarding Prometheus Biosciences' prospects. Prometheus Biosciences' investing sentiment can be driven by a variety of factors including economic data, Prometheus Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Theres no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Prometheus Biosciences...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Prometheus Biosciences Fundamental Analysis

We analyze Prometheus Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Prometheus Biosciences is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Prometheus Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prometheus Biosciences stock to make a market-neutral strategy. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics with similar companies.

Peers

Prometheus Biosciences Related Equities

PLRXPliant Therapeutics   4.49   
0%
79.0%
VKTXViking Therapeutics   3.06   
0%
54.0%
ACLXArcellx   1.88   
0%
33.0%
ETNB89bio   1.19   
0%
21.0%
IMVTImmunovant   0.85   
0%
15.0%
AKROAkero Therapeutics   0.40   
0%
7.0%
KRYSKrystal Biotech   0.00   
0%
0%
AMLXAmylyx Pharmaceuticals   0.94   
16.0%
0%
BPMCBlueprint Medicines   1.07   
18.0%
0%
APLSApellis Pharmaceuticals   1.25   
22.0%
0%
TERNTerns Pharmaceuticals   1.86   
32.0%
0%
ROIVRoivant Sciences   2.08   
36.0%
0%
STOKStoke Therapeutics   3.39   
59.0%
0%
DAWNDay One   4.36   
77.0%
0%
MDGLMadrigal Pharmaceuticals   5.66   
100.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk